• Guidance
  • Interesting shortcuts
  • EFFRA Members' Perspectives
  • News Dashboard
  • Structured Wiki
    • Search
    • FoF and Made in Europe Partnership
    • Demonstrators, pilots, prototypes
    • Exploitable result(s)
    • Significant innovations and lessons learned, training aspects
    • Report - Video - Presentation - Publication....?
    • Project clusters
    • EFFRA member perspectives
    • Manufacturing future products
    • Manufacturing performance characteristics
    • Technologies and enablers
    • ICT performance characteristics
    • Standards, technical committees and working groups
    • Contribution of R&I projects to standardisation
    • Regulatory and policy aspects
    • Standards - other classifications
    • Business model aspects
    • Pathways
    • MiE SRIA R&I Priorities
    • MiE WP26-27 Consultation - Potential Research Topics only
    • MiE WP26-27 Consultation and context pointers
    • MiE WP26-27 Consultation with pointers to WP25-27 consultation
    • MiE KPIs
    • Relevant (future) calls
    • EU-Programme-Call
    • NACE code
    • EFFRA Organisations - members
    • EFFRA WG pointers
  • Pathways
    • Pathways
  • Projects
    • Projects
  • Resources
    • Resources
  • Project ideas
    • Project ideas
  • People & organisations
    • People
    • Organisations
  • portal@effra.eu
  • Visit the EFFRA website
    • Login
  • Structured Wiki
  • EU-Programme-Call
  • Horizon 2020
  • H2020-EU.3. SOCIETAL CHALLENGES
  • H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
  • H2020-EU.3.1.3. Treating and managing disease
  • H2020-EU.3.1.3.0. Cross-cutting call topics

H2020-EU.3.1.3.0. Cross-cutting call topics

  • H2020-HCO-2014
    • HCO-04-2014 Support for international infectious disease preparedness research
    • HCO-05-2014 Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes
    • HCO-07-2014 ERA-NET: Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020
    • HCO-08-2014 ERA-NET: Aligning national/regional translational cancer research programmes and activities
    • HCO-10-2014 ERA NET rare disease research implementing IRDiRC objectives
  • H2020-HCO-2015
    • HCO-06-2015 Global Alliance for Chronic Diseases. Prevention and treatment of lung diseases
    • HCO-11-2015 ERA NET Collaboration and alignment of national programmes and activities in the area of brain-related diseases and disorders of the nervous system
    • HCO-12-2015 ERA NET: Antimicrobial resistance
    • HCO-13-2015 ERA-NET: Cardiovascular disease
    • HCO-17-2015 Towards sustainability and globalisation of the Joint Programming Initiative on Neurodegenerative Diseases
  • H2020-IBA-SC1-CORONAVIRUS-2020-3
    • IBA-SC1-CORONAVIRUS-2020-3
  • H2020-IBA-SC1-GACD-2018
    • IBA-SC1-GACD-2018
  • H2020-PHC-2014-single-stage
    • PHC-15-2014 Clinical research on regenerative medicine
  • H2020-PHC-2014-two-stage
    • PHC-10-2014 Development of new diagnostic tools and technologies: in vitro devices, assays and platforms
    • PHC-13-2014 New therapies for chronic non-communicable diseases
    • PHC-17-2014 Comparing the effectiveness of existing healthcare interventions in the elderly
  • H2020-PHC-2015-single-stage_RTD
    • PHC-15-2015 Clinical research on regenerative medicine
  • H2020-PHC-2015-two-stage
    • PHC-11-2015 Development of new diagnostic tools and technologies: in vivo medical imaging technologies
    • PHC-14-2015 New therapies for rare diseases
    • PHC-16-2015 Tools and technologies for advanced therapies
    • PHC-18-2015 Establishing effectiveness of health care interventions in the paediatric population
  • H2020-SC1-2016-RTD
    • SC1-PM-09-2016 New therapies for chronic diseases
    • SC1-PM-11-2016-2017 Clinical research on regenerative medicine
  • H2020-SC1-2016-RTD-Zika
    • SC1-PM-22-2016 Addressing the urgent research gaps against the Zika virus and other emerging threats in Latin America
  • H2020-SC1-2017-Single-Stage-RTD
    • SC1-HCO-07-2017 Global Alliance for Chronic Diseases (GACD) prevention and management of mental disorders
    • SC1-PM-11-2016-2017 Clinical research on regenerative medicine
  • H2020-SC1-2017-Two-Stage-RTD
    • SC1-PM-08-2017 New therapies for rare diseases
    • SC1-PM-10-2017 Comparing the effectiveness of existing healthcare interventions in the adult population
  • H2020-SC1-2018-Single-Stage-RTD
    • SC1-BHC-04-2018 Rare Disease European Joint Programme Cofund
    • SC1-BHC-09-2018 Innovation platforms for advanced therapies of the future
    • SC1-BHC-16-2018 Global Alliance for Chronic Diseases (GACD) - Scaling-up of evidence-based health interventions at population level for the prevention and management of hypertension and/or diabetes
    • SC1-BHC-18-2018 Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC)
    • SC1-BHC-23-2018 Novel patient-centred approaches for survivorship, palliation and/or end-of-life care
  • H2020-SC1-2018-Two-Stage-RTD
    • SC1-BHC-15-2018 New anti-infective agents for prevention and/or treatment of neglected infectious diseases (NID)
  • H2020-SC1-2019-Single-Stage-RTD
    • SC1-BHC-07-2019 Regenerative medicine: from new insights to new applications
    • SC1-HCO-15-2019 Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)
  • H2020-SC1-2019-Two-Stage-RTD
    • SC1-BHC-14-2019 Stratified host-directed approaches to improve prevention, treatment and/or cure of infectious diseases
  • H2020-SC1-PHE-CORONAVIRUS-2020
    • SC1-PHE-CORONAVIRUS-2020
  • H2020-SMEINST-1-2014
    • PHC-12-2014-1 Clinical research for the validation of biomarkers and/or diagnostic medical devices
  • H2020-SMEINST-1-2015
    • PHC-12-2015-1 Clinical research for the validation of biomarkers and/or diagnostic medical devices
  • H2020-SMEINST-1-2016-2017
    • SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
  • H2020-SMEINST-2-2014
    • PHC-12-2014 Clinical research for the validation of biomarkers and/or diagnostic medical devices
  • H2020-SMEINST-2-2015
    • PHC-12-2015 Clinical research for the validation of biomarkers and/or diagnostic medical devices
  • H2020-SMEINST-2-2016-2017
    • SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
Powered by Chris Decubber BV